1-12 of 12
Stephan Stilgenbauer, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reduced c-FOS Is Associated with Poor Prognosis and Clinical Course in Chronic Lymphocytic Leukemia

Christopher C Oakes, Ph.D,, Rainer Claus, Christopher Schmidt, Yoon Jung Park, Ph.D., Michael Boutros, Dr., Stephan Stilgenbauer, M.D., Christoph Plass
Journal: Blood
Blood (2011) 118 (21): 2433.
https://doi.org/10.1182/blood.V118.21.2433.2433
Published: 2011
Journal Articles

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Natali Pflug, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Dirk Winkler, MD, Andreas Buehler, MD, Myriam Mendila, MD, Michael Wenger, MD, Hartmut Dohner, MD, Stephan Stilgenbauer, M.D., Michael Hallek, MD, Kirsten Fischer, MD
Journal: Blood
Blood (2010) 116 (21): 918.
https://doi.org/10.1182/blood.V116.21.918.918
Published: 2010
Journal Articles

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

Stephan Stilgenbauer, M.D., Florence Cymbalista, Véronique Leblond, Alain Delmer, MD, Thorsten Zenz, MD, Dirk Winkler, Andreas Bühler, Silja Mack, Raymonde Busch, Stefan Ibach, Sylvain Choquet, MD, Caroline Dartigeas, Bruno Cazin, MD, Olivier Tournilhac, MD, PhD, Michael Rieger, Martin Sökler, Till Seiler, Johannes Schetelig, Peter Dreger, MD, PhD, Michael Hallek, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2010) 116 (21): 920.
https://doi.org/10.1182/blood.V116.21.920.920
Published: 2010
Journal Articles

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

William G. Wierda, MD, PhD, Thomas J. Kipps, MD, PhD, Jiri Mayer, MD, PhD, Tadeusz Robak, MD, PhD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Richard R. Furman, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Stephan Stilgenbauer, M.D., Catherine D. Williams, FRCPath, Marek Trneny, MD, PhD, Guillaume Cartron, MD, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Swaminathan Padmanabhan, MBBS, MS, Geoffrey W. Chan, MD, Ira V. Gupta, MD, Michele M. Gorczyca, MS, Randy L. Davis, DrPH, Nedjad Losic, MSc, Steen Lisby, MD, DMSC, Anders Österborg, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 921.
https://doi.org/10.1182/blood.V116.21.921.921
Published: 2010
Journal Articles

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Clemens Wendtner, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Daruka Mahadevan, MD, PhD, Stephan Stilgenbauer, M.D., Lutz Uharek, Steven Coutre, Olga Frankfurt, Adrian Bloor, PhD, MRCP, FRCPath, Francesc Bosch, MD, PhD, Richard R. Furman, MD, Eva Kimby, John G. Gribben, MD, DSc, Marco Gobbi, MD, Luke Dreisbach, MD, David Duane Hurd, MD, Mikkael A. Sekeres, MD, MS, Alessandra Ferrajoli, MD, Sheetal Shah, Jennie Zhang, Laure Moutouh de Parseval, MD, Asher A. Chanan-Khan
Journal: Blood
Blood (2010) 116 (21): 1376.
https://doi.org/10.1182/blood.V116.21.1376.1376
Published: 2010
Journal Articles

Maturation of the miR15a/miR16-1 Family Is Impaired In Chronic Lymphocytic Leukaemia

Daniel Mertens, PhD, Danilo Allegra, Angela Philippen, Thorsten Zenz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, M.D.
Journal: Blood
Blood (2010) 116 (21): 53.
https://doi.org/10.1182/blood.V116.21.53.53
Published: 2010
Journal Articles

Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

Mark C Lanasa, MD, PhD, Leslie Andritsos, MD, Jennifer R Brown, MD, PhD, Janice Gabrilove, M.D., Federico Caligaris-Cappio, M.D., Richard Larson, M.D., Thomas J. Kipps, MD, PhD, Veronique Leblond, M.D., Donald Milligan, MD, FRCP, FRCPath, Ann Janssens, M.D., Nyla A. Heerema, Ph.D., Stephan Stilgenbauer, M.D., John C. Byrd, MD, Michael R. Grever, M.D.
Journal: Blood
Blood (2010) 116 (21): 58.
https://doi.org/10.1182/blood.V116.21.58.58
Published: 2010
Journal Articles

IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)

Andreas Bühler, MD, Thorsten Zenz, MD, Dirk Winkler, MD, Raymonde Busch, Kirsten Fischer, MD, Anna Fink, MD, Clemens Wendtner, Barbara Eichhorst, Jennifer Edelmann, MD, Michael Hallek, Hartmut Doehner, MD, Stephan Stilgenbauer, M.D.
Journal: Blood
Blood (2010) 116 (21): 3609.
https://doi.org/10.1182/blood.V116.21.3609.3609
Published: 2010
Journal Articles

Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network ( MCL net )

Olivier Hermine, MD, PhD, Eva Hoster, Jan Walewski, Vincent Ribrag, MD, Nicole Brousse, Catherine Thieblemont, MD, Reda Bouabdallah, Stephan Stilgenbauer, M.D., Pierre Feugier, MD, PhD, Roswitha Forstpointner, MD, Corinne Haioun, MD, Michael Kneba, MD, PhD, Mathias Hänel, Rene-Olivier Casasnovas, MD, Jürgen Finke, MD, Michael Hallek, MD, Hannes Wandt, MD, Andre Bosly, MD, Wolfram Klapper, MD, Christian Gisselbrecht, MD, Bertrand Coiffier, MD, PhD, Wolfgang Hiddemann, MD, PhD, Michael Unterhalt, MD, PhD, Martin H. Dreyling, MD
Journal: Blood
Blood (2010) 116 (21): 110.
https://doi.org/10.1182/blood.V116.21.110.110
Published: 2010
Journal Articles

Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study

Frank G. Rücker, Stephan Stilgenbauer, M.D., Martin Bommer, Daniela Späth, Silja Mack, Konstanze Döhner, Hartmut Döhner, MD, Richard F. Schlenk, MD
Journal: Blood
Blood (2010) 116 (21): 2184.
https://doi.org/10.1182/blood.V116.21.2184.2184
Published: 2010
Journal Articles

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Thorsten Zenz, MD, Peter Dreger, MD, PhD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Matthias Ritgen, MD, Dirk Winkler, MD, Andreas Bühler, MD, Donald Bunjes, MD, Dietrich Beelen, MD, Sandra Cohen, MD, FRCPC, Ute Hegenbart, MD, Matthias Zeis, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, M.D.
Journal: Blood
Blood (2010) 116 (21): 2357.
https://doi.org/10.1182/blood.V116.21.2357.2357
Published: 2010
Journal Articles

Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.

Christine Mayr, MD, Cathrine Schulz, M.D., Stephan Stilgenbauer, M.D., Alexander Kröber, M.D., Hartmut Döhner, M.D., Ulrich Jäger, M.D., Birgit Kainz, M.D., Georg Hopfinger, M.D., Rüdiger Hoffmann, M.D., Clemens Wendtner, M.D., Michael Hallek, M.D., Michael R. Speicher, M.D.
Journal: Blood
Blood (2006) 108 (11): 2084.
https://doi.org/10.1182/blood.V108.11.2084.2084
Published: 2006